What Is Opdivo Qvantig (Subcutaneous Nivolumab)? FDA Approval, Licensing and Reimbursement in Türkiye

FDA Approval: Yes. First Approval Date: December 27, 2024

Brand Name: Opdivo Qvantig

Active Ingredients: Nivolumab and recombinant human hyaluronidase (rHuPH20)

Route of Administration: Subcutaneous (under-the-skin) injection

Class: Programmed death receptor-1 (PD-1) inhibitor

Category: Immune checkpoint inhibitor (immunotherapy)

Manufacturer: Bristol Myers Squibb

Distribution in Türkiye: Not yet licensed in Türkiye.

Approved Cancer Types: Opdivo Qvantig is approved for subcutaneous use in many solid-tumor indications previously approved for intravenous (IV) Opdivo, including:

• Melanoma: Adjuvant treatment of completely resected Stage IIB, IIC, III, or IV melanoma. Unresectable or metastatic melanoma.
• Renal Cell Carcinoma (RCC): First-line treatment of advanced RCC. RCC after antiangiogenic therapy
• Lung Cancer: Unresectable or metastatic non-small cell lung cancer (NSCLC). As neoadjuvant and adjuvant treatment
• Head and Neck Squamous Cell Carcinoma (HNSCC): Advanced or metastatic HNSCC after platinum-based treatment
• Urothelial Carcinoma (Bladder Cancer): Adjuvant treatment in high-risk patients after radical resection. First-line treatment in advanced or metastatic disease. Disease progression after platinum-based treatment.
• Gastric, Gastroesophageal Junction, and Esophageal Cancers: Adjuvant treatment for residual disease after neoadjuvant chemoradiotherapy. First-line treatment in advanced or metastatic disease
• Colorectal Cancer: Metastatic colorectal cancer with high microsatellite instability (MSI-H) or deficient DNA mismatch repair (dMMR)
• Hepatocellular Carcinoma (HCC): Treatment after sorafenib.
• Malignant Pleural Mesothelioma: First-line treatment of unresectable disease

What Is Opdivo Qvantig (Subcutaneous Nivolumab) and How Does It Work?

Opdivo Qvantig is a subcutaneous formulation of the cancer immunotherapy nivolumab combined with recombinant human hyaluronidase (rHuPH20). Nivolumab is a monoclonal antibody targeting the programmed cell death 1 (PD-1) receptor and belongs to the immune checkpoint inhibitor class. Opdivo Qvantig was developed to have the same biological efficacy as intravenous (IV) Opdivo, with the advantage of subcutaneous administration over approximately 3-5 minutes.

How Does It Work?

The mechanism of Opdivo Qvantig relies on synergy between two main components:

• Nivolumab (Anti-PD-1 Antibody): PD-1 is a checkpoint receptor on T-cell surfaces. Cancer cells activate this pathway by expressing PD-L1/PD-L2 ligands, preventing T cells from killing them. Nivolumab binds to PD-1 and blocks this interaction, reactivating the immune system so T cells can recognize and destroy tumor cells.
• Recombinant Human Hyaluronidase (rHuPH20): This enzyme breaks down hyaluronan in subcutaneous tissue, increasing tissue permeability. It allows large-molecule drugs such as monoclonal antibodies to disperse more rapidly and effectively beneath the skin, facilitating efficient subcutaneous absorption of nivolumab.

FDA (US Food and Drug Administration) Approval History

December 27, 2024: The FDA approved subcutaneous Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) for most solid-tumor indications previously approved for Opdivo (nivolumab).

Licensing in Türkiye

It is not currently officially licensed in Türkiye, although access through overseas medicine procurement may be possible. It is not on the current “Active Overseas Medicines List” published by the Turkish Pharmacists' Association (TEB).

Mechanisms of Resistance

• An Immunosuppressive Tumor Microenvironment (TME): The tumor microenvironment may contain suppressive cells such as Tregs and MDSCs that prevent T-cell entry and activity. Full immune activation may not occur even with PD-1 blockade.
• Low or Absent PD-L1 Expression: Nivolumab blocks the PD-1/PD-L1 interaction. However, some tumors produce little or no PD-L1, in which case PD-1 blockade does not work.
• Impaired Antigen Presentation: Tumor cells must present tumor antigens through MHC (HLA) class I molecules to be recognized by T cells. Loss of antigen-presentation components such as β2-microglobulin (B2M) prevents T-cell recognition and allows immune escape.
• Mutations in the JAK/STAT Pathway: Mutations in JAK1/JAK2 genes involved in interferon signaling disrupt interferon-γ-mediated immune responses. Even when T-cell activity reaches the tumor, tumor cells remain unaffected and resistance develops.
• Activation of Alternative Immune-Escape Pathways:The tumor can activate checkpoints other than PD-1/PD-L1, such as LAG-3, TIM-3, or TIGIT, allowing immune escape despite PD-1 blockade.
• The Tumor Cell's Immune-Related Genetic Profile: “Cold tumors,” with low T-cell infiltration and limited immune access, such as pancreatic cancer, are naturally resistant to immunotherapy.

Absorption

• Administration route: subcutaneous (SC) injection.
• Absorption profile: recombinant human hyaluronidase (rHuPH20) enables rapid, efficient absorption of a large antibody volume from beneath the skin.
• Tmax (time to maximum plasma concentration): generally reached within 2–7 days.
• Bioavailability: Approximately 82%, close to the level achieved intravenously.
• SC absorption is slow and prolonged, maintaining more stable plasma levels.

Distribution

• Volume of distribution (Vd): approximately 8 L, indicating limited extravascular distribution.
• Plasma protein binding: highly specific binding, but not extensive binding to plasma proteins in the conventional small-drug sense.
• Concentrates particularly in the lymphatic system and areas of high immune activity in the tumor microenvironment.

Metabolism

• Nivolumab is not a small-molecule drug and is therefore not metabolized by conventional hepatic enzymes such as CYP450.
• It is naturally broken down like endogenous IgG antibodies, undergoing lysosomal proteolysis into amino acids. This occurs primarily in the reticuloendothelial system (RES).

Elimination

• Half-life (t½): an average of 25 days (may range from 20–30 days).
• Elimination route: not excreted unchanged through the kidneys or bile.
• It is fully catabolized like natural proteins in the body.
• With regular use, steady blood levels are reached in approximately 12 weeks.
• Its long half-life generally allows administration every 2, 3, or 4 weeks.
• The subcutaneous formulation's pharmacokinetic profile has been optimized to be equivalent to the IV formulation.

Dose Range

• General Dose (for All Approved Solid-Tumor Indications): Nivolumab 600 mg + hyaluronidase-nvhy 10,000 U / 5 mL
• Administration: Subcutaneous injection may be given once weekly, every 3 weeks, or every 4 weeks, depending on the indication.
• Administration duration: Approximately 3–5 minutes

Drug Interactions

• Immunosuppressive Drugs: Immunosuppressants such as corticosteroids (e.g., prednisone), cyclosporine, and tacrolimus may reduce Opdivo Qvantig's effect by suppressing immunity and preventing T-cell activation. High-dose systemic corticosteroids should be used only in emergencies and for short periods.
• Other Immune Checkpoint Inhibitors (in Combinations): For example, combining it with ipilimumab (anti-CTLA-4) increases efficacy but also the risk of immune-related adverse events (irAEs). Patients receiving combination treatment require close monitoring.
• Live Vaccines: Live viral or bacterial vaccines, such as live influenza, BCG, and MMR vaccines, may alter the immune response. Live vaccines should not be given during immunotherapy.
• Drugs That Can Trigger Infection: Biological agents such as TNF inhibitors can reactivate latent infections, including tuberculosis. Concurrent use with Opdivo may increase infection risk.
• Hematologic Drugs and Chemotherapy: Concurrent cytotoxic agents may weaken or mask the immune response.

Points Requiring Attention

• Autoimmune Diseases: In patients with pre-existing active autoimmune disease, such as lupus, rheumatoid arthritis, or inflammatory bowel disease (IBD), immunotherapy may cause a flare. Use requires caution, or alternative treatments should be considered.
• Patients with Organ Transplants: Immune activation may cause graft rejection, particularly after kidney or liver transplantation. Use is generally not recommended in organ transplant recipients.
• Patients Receiving Immunosuppressive Treatment: High-dose corticosteroids or other immunosuppressive treatments may reduce nivolumab's immune-activating effect. If corticosteroids are not essential, low doses and short durations should be used where possible.
• Live Vaccines: Immunotherapies such as nivolumab may adversely affect the safety and efficacy of live vaccines. Live vaccines, such as MMR, yellow fever, and BCG, should not be administered during treatment.
• Pregnancy and Breastfeeding: Nivolumab is thought to cross the placental barrier. Excretion in breast milk is unknown, but an effect on the immune system is assumed. It should not be used in pregnancy and is not recommended during breastfeeding.
• Kidney and Liver Impairment: Because nivolumab is not eliminated through the liver or kidneys, dose adjustment is generally unnecessary. However, liver function should be monitored in advanced liver disease. Increased liver enzymes may indicate immune-mediated hepatitis.
• Special Considerations for Subcutaneous Administration: If skin integrity is compromised at the administration site, for example by dermatitis, ulceration, or infection, injection should be postponed or an alternative site used. Injection-site reactions such as redness, induration, or pain are generally mild but require monitoring.
• Risk of Immune-Mediated Adverse Reactions: Systemic toxicities during Opdivo Qvantig use may include pneumonitis, colitis, hepatitis, thyroiditis, dermatitis, and nephritis. Patients should be closely monitored, with early intervention, such as steroid treatment, when symptoms develop.

Adverse Reactions

These reactions may vary by patient and indication. Immune-mediated adverse reactions, such as pneumonia, colitis, and thyroiditis, can generally be controlled through early recognition and intervention.

• Fatigue 35%
• Diarrhea 26%
• Itching 22%
• Rash 20%
• Nausea 19%
• Loss of appetite 18%
• Thyroid disorders (hypothyroidism / hyperthyroidism) 15%
• Musculoskeletal pain (arthralgia, myalgia) 14%
• Cough 13%
• Fever 12%
• Vomiting 11%
• Weakness 10%
• Injection-site reactions 10%
• Headache 9%
• Increased liver enzymes (AST/ALT) 8%
• Hyponatremia 7%
• Nephritis (kidney inflammation) 5%
• Pneumonia (lung inflammation) 3–5%
• Immune-mediated colitis 3–4%
• Endocrine disorders (hypophysitis, adrenal insufficiency) 2–3%
• Severe skin reactions (such as toxic epidermal necrolysis) <1%
• Anaphylaxis / hypersensitivity reactions <1%